The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials

Expert Opinion on Investigational Drugs

Volumn 23, Issue 11, 2014, Pages 1517-1529

  Synakiewicz, Anna ^a   Stachowicz Stencel, Teresa ^a   Adamkiewicz Drozynska, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Arginine; Arginine deiminase; Cancer; Clinical trials; Targeted anticancer therapy

Indexed keywords

ARGININE; PEGARGIMINASE; ANTINEOPLASTIC AGENT; HYDROLASE; MACROGOL DERIVATIVE;

AMINO ACID METABOLISM; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PROGNOSIS; CANCER THERAPY; DRUG METABOLISM; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIOMA; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PROCESSING; REVIEW; SYSTEMATIC REVIEW; ANIMAL; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTINEOPLASTIC AGENTS; ARGININE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; HYDROLASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84911473209     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.934808     Document Type: Review

References (97)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
2. Warburg O. Origin of cancer cells. Oncologia 1956;9(2):75-83
3. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011;10:671-84
4. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7
5. Stass SA, Mixson J. Oncogenes and tumor suppressor genes: therapeutic implications. Clin Cancer Res 1997; 3:2687-95
6. Chiaradonna F, Moresco RM, Airoldi C, et al. From cancer metabolism to new biomarkers and drug targets. Biotechnol Adv 2012;30(1):30-51
7. Tennant DA, Duran RV, Boulahbel H, et al. Metabolic transformation in cancer. Carcinogenesis 2009;30:1269-80
8. King A, Gottlieb E. Glucose metabolism and programmed cell death: an evolutionary and mechanistic perspective. Curr Opin Cell Biol 2009;21:885-93
9. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010;10(4):267-77
10. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr 2008;27:328-39
11. Reeds PJ, Burrin DG, Stoll B, et al. Intestinal glutamate metabolism. J Nutr 2000;130:978-82
12. Crenn P, Coudray-Lucas C, Thuillier F, et al. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000;119:1496-505
13. Cynober LA. Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition 2002;18:761-6
14. Wu G, Bazer FW, Davis TA, et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009; 37:153-68
15. Coeffier M, Marion-Letellier R, Dechelotte P. Potential for amino acids supplementation during inflammatory bowel diseases. Inflamm Bowel Dis 2009;16:518-24
16. Dechelotte P, Hasselmann M, Cynober L, et al. L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study. Crit Care Med 2006;34:598-604
17. Marion R, Coeffier M, Leplingard A, et al. Cytokine-stimulated nitric oxide production and inducible NO-synthase mRNA level in human intestinal cells: lack of modulation by glutamine. Clin Nutr 2003;22:523-8
18. Brasse-Lagnel C, Lavoinne A, Loeber D, et al. Glutamine and interleukin-1beta interact at the level of Sp1 and nuclear factor-kappa B to regulate argininosuccinate synthetase gene expression. FEBS J 2007;274:5250-62
19. Wu G. Amino acids: metabolism, functions, and nutrition. Amino Acids 2009;37:1-17
20. Lee J, Ryu H, Ferrante RJ, et al. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci USA 2003;100:4843-8
21. Lind DS. Arginine and cancer. J Nutr 2004;134(10 Suppl):2837-41
22. Mori M. Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J Nutr 2007;137:1616-20
23. Graboń W. Arginine as a crucial amino acid in carcinogenesis and tumor growth. Postepy Hig Med Dosw 2006;60:483-9
24. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in tumor angiogenesis. Cancer Treat Res 2004;117:155-67
25. Bertolo RF, Brunton JA, Pencharz PB, et al. Arginine, ornithine, and proline interconversion is dependent on small intestinal metabolism in neonatal pigs. Am J Physiol Endocrinol Metab 2003;284:915-22
26. Urschel KL, Rafii M, Pencharz PB, et al. A multitracer stable isotope quantification of the effects of arginine intake on whole body arginine metabolism in neonatal piglets. Am J Physiol Endocrinol Metab 2007;293:811-18
27. Tomlinson C, Rafii M, Sgro M, et al. Arginine is synthetized from proline not glutamate in enterally fed preterm human infants. FASEB J 2008;22:869-28
28. Wu G. Synthesis of citrulline and arginine from proline in enterocytes of postnatal pigs. Am J Physiol 1997;272:1382-90
29. Closs EI, Simon A, Vékony N, et al. Plasma membrane transporters for arginine. J Nutr 2004; 134(10 Suppl): 2752-9
30. van de Poll MC, Soeters PB, Deutz NE, et al. Renal metabolizm of amino acids: its role in interorgan amino acid exchange. Am J Clin Nutr 2004;79:185-97
31. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in tumor angiogenesis. Cancer Treat Res 2004;117:155-67
32. Vallance P, Leone A, Calver A, et al. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992;20(Suppl 12):60-2
33. Osanai T, Saitoh M, Sasaki S, et al. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003;42:985-90
34. Usui M, Matsuoka H, Miyazaki H, et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998;62:2425-30
35. Fujiwara N, Osanai T, Kamada T, et al. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension : modulation of nitric oxide synthesis by salt intake. Circulation 2000;101:856-61
36. Mittermayer F, Namiranian K, Pleiner J, et al. Acute Escherichia coli endotoxaemia decreases the plasma larginine/asymmetrical dimethylarginine ratio in humans. Clin Sci (Lond) 2004;106:577-81
37. Nijveldt RJ, Siroen MP, Teerlink T, et al. Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure?. J Nutr 2004;134:2848-52
38. Szende B, Tyihak E, Trezl L. Role of arginine and its methylated derivatives in cancer biology and treatment. Cancer Cell Int 2001;1:3
39. Wheatley DN, Philip R, Campbell E. Arginine deprivation and tumour cell death: arginase and its inhibition. Mol Cell Biochem 2000;244:177-85
40. Dillon BJ, Prieto VG, Curley SA, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004;100:826-33
41. Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004;22:1815-22
42. Ma QY, Hoper M, Anderson N, et al. Effect of supplemental L-arginine in a chemical induced model of colorectal cancer. World J Surg 1996;20:1087-95
43. Gonzaga Silva LF, Odorico de Moraes M, Santos Dias Soares F, et al. Effects of L-arginine-enriched total enteral nutrition on body weight gain, tumor growth, and in vivo concentrations of blood and tissue metabolites in rats inoculated with walker tumor in the kidney. Nutrition 2004;20:225-9
44. Ma Q, Wang Y, Gao X, et al. L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma. Clin Cancer Res 2007;13(24):7407-12
45. Nanthakumaran S, Brown I, Heys SD, et al. Inhibition of gastric cancer cell growth by arginine: molecular mechanisms of action. Clin Nutr 2009;28(1):65-70
46. Sperling MA, Saenger PH, Hinz R, et al. Lawson Wilkins Pediatric Endocrine Society. LWPES Executive Committee and the LWPES Drug and Therapeutics Committee. Growth hormone treatment and neoplasia-coincidence or consequence?. J Clin Endocrinol Metab 2002;87(12):5351-2
47. Melmed GY, Devlin SM, Vlotides G, et al. Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis. Clin Gastroenterol Hepatol 2008;6(3):360-3
48. Nishi Y, Tanaka T, Takano K, et al. Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan. J Clin Endocrinol Metab 1999;84(6):1961-5
49. Pekic S, Popovic V. GH therapy and cancer risk in hypopituitarism: what we know from human studies. Eur J Endocrinol 2013; 169(5):89-97
50. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metabol 2002;87(7):3136-41
51. Reynolds JV, Daly JM, Zhang S, et al. Immunomodulatory mechanisms of arginine. Surgery 1988;104:142-51
52. Kirk SJ, Regan MC, Wasserkrug HL, et al. Arginine enhance T-cell responses in athymic nude mice. Parenter Enteral Nutr 1992;16:429-32
53. Torre PM, Ronnenberg AG, Hartman WJ, et al. Oral arginine supplementation does not affect lymphocyte proliferation during endotoxin-induced inflammation in rats. J Nutr 1993;123:481-8
54. van Bokhorst-De Van Der Schueren MA, Quak JJ, von Blombergvan der Flier BM, et al. Effect of perioperative nutrition, with and without arginine supplementation, on nutritional status, immune function, postoperative morbidity, and survival in severely malnourished head and neck cancer patients. Am J Clin Nutr 2001;73:323-32
55. McCarter MD, Gentilini OD, Gomez ME, et al. Preoperative oral supplement with immunonutrients in cancer patients. J Parenter Enter Nutr 1998;22:206-11
56. Daly JM, Reynolds J, Thom A, et al. Immune and metabolic effects of arginine in the surgical patient. Ann Surg 1988;208:512-23
57. Sippel TR, White J, Nag K, et al. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res 2011;17(22):6992-7002
58. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8
59. Rodriguez PC, Ernstoff MS, Hernandez C, et al. ArginaseI-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69:1553-60
60. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanisms of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61:4756-60
61. Cheng PN, Leung YC, Lo WH, et al. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Lett 2005;224:67-80
62. Rogers QR. Species variation in arginine requirements. Proceedings from a Symposium Honoring Willard J. Visek - From Ammonia to Cancer and Gene Expression; Illinois, USA; 1994. p. 9-21. Special Publication 86
63. Takaku H, Matsumoto M, Misawa S, et al. Anti-tumor activity of arginine deiminase from Mycoplasma arginine and its growth-inhibitory mechanism. Jpn J Cancer Res 1995;86:840-6
64. Holtsberg FW, Ensor CM, Steiner MR, et al. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 2002;80:259-71
65. Shen LJ, Lin WC, Beloussow K, et al. Recombinant arginine deiminase as a differential modulator of inducible (iNOS) and endothelial (eNOS) nitric oxide synthetase activity in cultured endothelial cells. Biochem Pharmacol 2003;66(10):1945-52
66. Zhu L, Tee KL, Roccatano D, et al. Directed evolution of an antitumor drug (arginine deiminase PpADI) for increased activity at physiological pH. ChemBioChem 2010;11(5):691-7
67. Park IS, Kang SW, Shin YJ, et al. Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth. Br J Cancer 2003;89(5):907-14
68. Beloussow K, Wang L, Wu J, et al. Recombinant arginine deiminase as apotential anti-angiogenic agent. Cancer Lett 2002;183(2):155-62
69. Oz HS, Zhong J, de Villiers WJ. Pegylated arginine deiminase downregulates colitis in murine models. Mediators Inflamm 2012;2012:813892
70. Willis V, Gizinski A, Banda N, et al. N-alpha-benzoyl-N5-(2-chloro-1- iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol 2011;186(7):4396-404
71. Kidd B, Ho P, Sharpe O, et al. Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res Ther 2008;10(5):119
72. Gilroy E. The influence of arginine upon the growth rate of a transplantable tumour in the mouse. Biochem J 1930;24:589-95
73. Ascierto PA, Scala S, Castello G, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23:7660-8
74. Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci USA 1997;94:6954-8
75. Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat 2013;45(4):251-62
76. Bowles TL, Kim R, Galante J, et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 2008;123(8):1950-5
77. Szlosarek PW, Klabatsa A, Pallaska A, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006;12:7126-31
78. Brasse-Lagnel C, Fairand A, Lavoinne A, et al. Glutamine stimulates argininosuccinate synthetase gene expression through cytosolic Oglycosylation of Sp1 in Caco-2 cells. J Biol Chem 2002;278:52504-10
79. Szlosarek PW, Luong P, Phillips MM, et al. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol 2013;31(7):111-13
80. Yoon CY, Shim YJ, Kim EH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 2007;120(4):897-905
81. Glazer ES, Piccirillo M, Albino V, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010;28(13):2220-6
82. Yang TS, Lu SN, Chao Y, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010;103(7):954-60
83. Yau T, Cheng PN, Chan P, et al. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs 2013;31(1):99-107
84. Kim RH, Coates JM, Bowles TL, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 2009;69(2):700-8
85. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006;66:10040-7
86. Feun LG, Marini A, Walker G, et al. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from argininedepleting therapy with pegylated arginine deiminase. Br J Cancer 2012;106(9):1481-5
87. Ott PA, Carvajal RD, Pandit-Taskar N, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG20) in patients with advanced melanoma. Invest New Drugs 2013;31(2):425-34
88. Kelly MP, Jungbluth AA, Wu BW, et al. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer 2012;106(2):324-32
89. Cendan JC, Topping DL, Pruitt J, et al. Inflammatory mediators stimulate arginine transport and arginine-derived nitric oxide production in a murine breast cancer cell line. J Surg Res 1996;60:284-8
90. Stechmiller JK, Childress B, Porter T. Arginine immunonutrition in critically ill patients: a clinical dilemma. Am J Crit Care 2004;13:17-23
91. Heys SD, Walker LG, Smith I, et al. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. Ann Surg 1999;229:467-77
92. Hibbs Jr JB, Vavrin Z, Taintor RR. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells.J Immunol. 1987;138:550-65
93. Brittenden J, Heys SD, Eremin O. L-arginine and malignant disease: a potential therapeutic role?. Eur J Surg Oncol 1994;20:189-92
94. Cho-Chung YS, Clair T, Bodwin JS, et al. Growth arrest and morphological change of human breast cancer cells by dibutyryl cyclic AMP and L-arginine. Science 1981;214:77-9
95. Delage B, Fennell DA, Nicholson L, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 2010;126(12):2762-72
96. Tsai WB, Aiba I, Lee SY, et al. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1 alpha/Sp4. Mol Cancer Ther 2009;8(12):3223-33
97. ClinicalTrials.gov. Available from: https://clinicaltrials.gov